Product Center
Further advances in orthopoxvirus mRNA vaccines
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-04-12
- Views:
(Summary description)From April 2 to April 4, 2024, Dr. Xiong Nolin, Deputy General Manager of EW BioTech (Shanghai) Co., Ltd (hereinafter referred to as EW Bio), a wholly-owned subsidiary of Jiangsu Zhonghui Yuantong Bio-Technology Co., Ltd (hereinafter referred to as EW Bio), was invited to participate in the World Vaccine Congress 2024, where he made a keynote speech and exchanged the results of the company's important R & D project of the Orthopoxvirus mRNA vaccine, which was received by the international counterparts with great interest and recognition.
Further advances in orthopoxvirus mRNA vaccines
(Summary description)From April 2 to April 4, 2024, Dr. Xiong Nolin, Deputy General Manager of EW BioTech (Shanghai) Co., Ltd (hereinafter referred to as EW Bio), a wholly-owned subsidiary of Jiangsu Zhonghui Yuantong Bio-Technology Co., Ltd (hereinafter referred to as EW Bio), was invited to participate in the World Vaccine Congress 2024, where he made a keynote speech and exchanged the results of the company's important R & D project of the Orthopoxvirus mRNA vaccine, which was received by the international counterparts with great interest and recognition.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-04-12 10:20
- Views:
From April 2 to April 4, 2024, Dr. Xiong Nolin, Deputy General Manager of EW BioTech (Shanghai) Co., Ltd (hereinafter referred to as EW Bio), a wholly-owned subsidiary of Jiangsu Zhonghui Yuantong Bio-Technology Co., Ltd (hereinafter referred to as EW Bio), was invited to participate in the World Vaccine Congress 2024, where he made a keynote speech and exchanged the results of the company's important R & D project of the Orthopoxvirus mRNA vaccine, which was received by the international counterparts with great interest and recognition.
On April 5, 2024, the research results were reviewed by international peer experts and published under the title of "A Quadrivalent mRNA Immunization Elicits Potent Immune Responses against Multiple Orthopoxviral Antigens and Neutralization of Monkeypox Virus in Rodent Models" was formally published in vaccines, an international journal of vaccinology; in addition, Zhonghui Bio and Yiwei Bio jointly applied for a research project entitled "Monkeypox Virus mRNA Vaccine and its Effectiveness". In addition, a patent application jointly filed by Zhonghui Biotech and E-Hui Biotech, entitled "Monkeypox Virus mRNA Vaccine and Its Use", was authorized by the State Intellectual Property Office of the People's Republic of China (State Intellectual Property Office of China) on April 5, 2024
 |
 |
Orthopoxviruses are a group of enveloped DNA viruses belonging to the Poxviridae family, which includes the smallpox virus that caused a global pandemic and the monkeypox virus that became endemic in 2022. Currently, there is a serious risk of monkeypox virus epidemics, and other viruses in the genus Orthopoxvirus are also at risk of infecting humans. However, the efficacy of the existing smallpox vaccine against monkeypox needs to be further verified, and the current stockpile and production of smallpox vaccine is extremely limited. In order to cope with the frequent emergence and pandemic of monkeypox and other potential outbreaks of smallpox virus, our technical team has designed and developed a new 4-valent smallpox virus mRNA vaccine through in-depth research of smallpox virus, which has been proved to be able to induce a good immune response through the immunization of animals and can cross-react with a variety of cognate proteins such as monkeypox virus and neutralize the monkeypox virus with high efficiency. monkeypox virus. In addition, the high level of neutralizing antibodies induced by this vaccine candidate in mice and rats was persistent, suggesting that it could be a good candidate for the prevention of monkeypox virus and other orthopoxvirus infections. Compared with the traditional design strategy of mixing multivalent mRNA antigens, the design strategy of encoding quadrivalent antigens with one mRNA by our team greatly simplifies the process development and reduces the cost of product development while taking into account the excellent pharmacodynamic properties of the vaccine, which provides a strong advantage in the industrialization of the vaccine in the future.
Relevant information
-
Further advances in orthopoxvirus mRNA vaccinesFrom April 2 to April 4, 2024, Dr. Xiong Nolin, Deputy General Manager of EW BioTech (Shanghai) Co., Ltd (hereinafter referred to as EW Bio), a wholly-owned subsidiary of Jiangsu Zhonghui Yuantong Bio-Technology Co., Ltd (hereinafter referred to as EW Bio), was invited to participate in the World Vaccine Congress 2024, where he made a keynote speech and exchanged the results of the company's important R & D project of the Orthopoxvirus mRNA vaccine, which was received by the international counterparts with great interest and recognition. - Huierkangxin has been selected for the 2024 Jiangsu Province Innovative Pharmaceutical Equipment Special Award List! 03-08
- Received national level praise! 03-01
- Recombinant herpes zoster vaccine (CHO cell) IND application accepted 02-23
- Ab&B Bio Tech CO., LTD. JS invited to attend the China Ukraine Trade Cooperation Seminar 11-28
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
